Next Article in Journal
iRSpot-TNCPseAAC: Identify Recombination Spots with Trinucleotide Composition and Pseudo Amino Acid Components
Next Article in Special Issue
The Neuroprotective Role of Acupuncture and Activation of the BDNF Signaling Pathway
Previous Article in Journal
Regulation of an Autoimmune Model for Multiple Sclerosis in Th2-Biased GATA3 Transgenic Mice
Previous Article in Special Issue
Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury
Open AccessReview

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

1
Field Neurosciences Institute Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA
2
Field Neurosciences Institute, Saginaw, MI 48604, USA
3
College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(2), 1719-1745; https://doi.org/10.3390/ijms15021719
Received: 2 December 2013 / Revised: 18 December 2013 / Accepted: 14 January 2014 / Published: 23 January 2014
(This article belongs to the Special Issue Pathology and Treatment of Central Nervous System Diseases)
The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs. View Full-Text
Keywords: mesenchymal stem cells; genetic engineering; Parkinson’s; Alzheimer’s; Huntington’s; neurodegenerative diseases; transplantation; glial cell-derived neurotrophic factor (GDNF); brain derived neurotrophic factor (BDNF); nerve growth factor (NGF) mesenchymal stem cells; genetic engineering; Parkinson’s; Alzheimer’s; Huntington’s; neurodegenerative diseases; transplantation; glial cell-derived neurotrophic factor (GDNF); brain derived neurotrophic factor (BDNF); nerve growth factor (NGF)
MDPI and ACS Style

Wyse, R.D.; Dunbar, G.L.; Rossignol, J. Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases. Int. J. Mol. Sci. 2014, 15, 1719-1745. https://doi.org/10.3390/ijms15021719

AMA Style

Wyse RD, Dunbar GL, Rossignol J. Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases. International Journal of Molecular Sciences. 2014; 15(2):1719-1745. https://doi.org/10.3390/ijms15021719

Chicago/Turabian Style

Wyse, Robert D.; Dunbar, Gary L.; Rossignol, Julien. 2014. "Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases" Int. J. Mol. Sci. 15, no. 2: 1719-1745. https://doi.org/10.3390/ijms15021719

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop